Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-10-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma

NCT05508555

Malignant Pleural Mesothelioma Chemotherapy Effect

UNKNOWN NA

The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma

NCT01776385

Pleural Neoplasms Mesothelioma Pneumothorax +3 more

COMPLETED NA

Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)

NCT03517852

Peritoneal Carcinomatosis

COMPLETED NA

Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma

NCT05193006

Peritoneal Malignant Mesothelioma

UNKNOWN

Cohort Study on Nutritional, Metabolic, and Volumetric Assessment After Pancreaticoduodenectomy

NCT07159672

Periampullary Neoplasms Pancreatic Cancer Pancreaticoduodenectomy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Pleural Mesotheliomas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

marker CD74 and vascular endothelial growth factor VEGF

correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histopathological confirmation of malignant pleural mesothelioma .
* Full clinical data.
* Availability for follow up: Personal communication will be attempted in order to collect missing information.

3-The files of all patients will be reviewed to analyze the following :
* Operative data if done .
* Pathological review and immunohistochemistry.
* Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)
* Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\\S and MRI ).
* Treatment protocols applied: Radiotherapy and Chemotherapy.
* Response and survival after treatment .